Barry Cohen
Barry Cohen (RSS)
Health Care Writer

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

Read complete bio
Recent Articles

Overreacting to a Prostate Cancer Drug?

Feb. 3, 2012, 10:58 am EST – Medivation shares are soaring on positive test results. But investors may be getting ahead of reality here. More 

Amylin Gets a Boost From Its Diabetes Drug Approval

Jan. 31, 2012, 8:56 am EST – FDA approval of Bydureon -- a once-a-week injectable drug -- could make Amylin a takeover target for a Big Pharma. More 

Someone Has to Crunch All That Clinical Trial Data

Jan. 31, 2012, 6:30 am EST – That's where a slew of info-tech companies, ranging from giant Oracle to tiny BioClinica, come in. However, investing is them is no slam dunk. More 

Small Patient Population? Charge $400K a Year for Your Drug

Jan. 27, 2012, 2:47 pm EST – Companies like BioMarin Pharmaceutical are cashing in on rare diseases, where they can charge hundreds of thousands of dollars every year for their drugs. More 

Roche’s Hostile Bid for Illumina Could Reach $60 Per Share

Jan. 25, 2012, 3:37 pm EST – Swiss health care giant Roche made a hostile bid to buy Illumina for $44.50 per share, but many think that number will be higher when all is said and done. More 

Do Magic Mushrooms Hold the Key to Treating Depression?

Jan. 25, 2012, 7:50 am EST – Controversial British researcher touting use of "magic mushroom" compound psilocybin in treating depression as illegal drugs move further into pharma forefront. More 

If Novartis’ MS Drug Falters, Biogen Will Gain

Jan. 23, 2012, 11:38 am EST – After the deaths of 11 people who were taking the drug, concerns that Gilenya may cause heart problems has hit NVS hard, ending the stock's months-long upswing. More 

The Little Guys Are Pharma’s New Stars

Jan. 20, 2012, 11:58 am EST – Small and midsize drugmakers are where the action is -- in both research and M&A activity. For healthy dividends, however, Big Pharma still rules. More 

Despite Connecticut Change on Medicaid, Outlook Strong for Health Insurers

Jan. 19, 2012, 1:08 pm EST – Connecticut recently dropped private insurers from serving its Medicaid members, but many of the industry's big names are far from worried. More 

Are Pharma’s ‘Good Old Days’ Gone Forever?

Jan. 17, 2012, 1:19 pm EST – You bet they are: Patent losses, a higher bar for FDA approvals, and slew of smaller, nimbler rivals have reshaped the industry. More